Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) -results from ASCEND-2 and ASCEND-3

被引：0
|
作者：
Park, K. [1 ]
Tan, D. [2 ]
Ahn, M. -J. [3 ]
Yu, C. -J. [4 ]
Tsai, C. -M. [5 ]
Hida, T. [6 ]
Nishio, M. [7 ]
Branle, F. [8 ]
Emeremni, C. [9 ]
Mok, T. [10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] Natl Taiwan Univ, Dept Internal Med, Taipei 10764, Taiwan
[5] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[6] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[7] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo, Japan
[8] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland
[9] Novartis Pharma AG, Biometr & Data Management, E Hanover, NJ USA
[10] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419O
引用
收藏
页码：126 / 127
页数：2
相关论文
共 50 条
  • [41] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    TUMORI JOURNAL, 2016, 102 : S46 - S49
  • [42] Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
    Awad, Mark
    Mastini, Cristina
    Patino, Rafael
    Mologni, Luca
    Voena, Claudia
    Mussolin, Lara
    Mach, Stacy
    Adeni, Anika
    Lydon, Christine
    Janne, Pasi
    Chiarle, Roberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1163
  • [43] Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Breadner, D.
    Shanmuganatjan, S.
    Boldt, G.
    Blanchette, P.
    Raphael, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1034 - S1034
  • [44] Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
    Breadner, Daniel
    Blanchette, Phillip
    Shanmuganathan, Sumugan
    Boldt, Ronald Gabriel
    Raphael, Jacques
    LUNG CANCER, 2020, 144 : 57 - 63
  • [45] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [46] Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer
    Santoro, Armando
    Su, Wu-Chou
    Navarro, Alejandro
    Simonelli, Matteo
    Yang, James C. H.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Kang, Jin Hyoung
    DiDominick, Sarah
    Abdelhady, Ahmed
    Chen, Xueying
    Stammberger, Uz
    Felip, Enriqueta
    LUNG CANCER, 2022, 166 : 170 - 177
  • [47] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [48] BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)
    Pan, X.
    Kwon, C. S.
    Garib, S. A.
    Forsythe, A.
    Lin, H. M.
    VALUE IN HEALTH, 2019, 22 : S439 - S439
  • [49] ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
    Tsakonas, Georgios
    Kamali, Caroline
    De Petris, Luigi
    Friesland, Signe
    Lewensohn, Rolf
    Ekman, Simon
    CANCERS, 2020, 12 (07) : 1 - 10
  • [50] Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
    Xing, Puyuan
    Wang, Shouzheng
    Hao, Xuezhi
    Zhang, Tongtong
    Li, Junling
    ONCOTARGET, 2016, 7 (51) : 84666 - 84674
12345